Kalbitor
FDA Approves Firazyr to Treat Acute Attacks of Hereditary Angioedema »
"The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18
years and older.
HAE is cau"...
Read the FDA Approves Firazyr to Treat Acute Attacks of Hereditary Angioedema article »
Kalbitor
OVERDOSE
There have been no reports of overdose with KALBITOR (ecallantide injection) . HAE patients have received single doses up to 90 mg intravenously without evidence of dose-related toxicity. No deaths occurred in monkeys that received intravenous or subcutaneous doses up to 25 mg/kg (approximately 22 times the MRHD on an AUC basis).
CONTRAINDICATIONS
Do not administer KALBITOR (ecallantide injection) to a patient who has known clinical hypersensitivity to KALBITOR. [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 12/14/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Kalbitor Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
